ECG247 Smart Heart Sensor

Hjem
Norge
Lillesand
ECG247 Smart Heart Sensor

ECG247 is a medically certified sensor for continuous and long-term monitoring of heart rhythm to detect heart rhythm disorders.

The product is affordable, easy to use and effective. The sensor provides feedback to the user in real time and immediate notification if possible heart rhythm disorders are detected. ECG data is uploaded directly to a secure cloud storage and is easily accessible for healthcare professionals. The sensor is currently used by GPs, cardiologists and private and public hospitals. The product is also

available for self-testing and can be purchased online. ECG247 is developed and produced by the medical technology company Appsens AS. Together with Sørlandet Hospital HF, the University of Agder and a number of technology partners, AppSens has developed the innovative heart sensor ECG247. ECG247 is an advanced sensor where the electronics are reusable while the electrode is disposable. The electronics part of the sensor can therefore be reused for several tests or for several people. The sensor has advanced algorithms for automatic detection of all serious and common heart rhythm disorders. The software uses artificial intelligence to improve accuracy. The sensor has both high sensitivity and specificity, and is certified and CE-approved by DNV GL according to Medical Devices Directive class IIa.

07/05/2026

This week we are attending ESOC 2026 in Maastricht together with our local distributor Diagnostics BV and Huibers.

We are having many inspiring conversations with neurologists about how ECG247 can support daily clinical practice and help provide patients with longer monitoring periods than they often receive today.

It is inspiring to experience the great enthusiasm among neurologists here at the conference, and we truly appreciate all the valuable discussions, insights, and new connections.

26/09/2025

ECG247 is gaining momentum among German healthcare providers ❤️

While traditional ECG systems like Holter monitors—with wires and limited monitoring duration—are still widely used in Germany, there’s a growing shift toward modern solutions for detecting atrial fibrillation and other arrhythmias. This is especially relevant in cases where symptoms are irregular and infrequent.

ECG247 offers a significant improvement in patient experience:
The wireless patch allows patients to go about their daily lives—including showering—while being continuously monitored. This sets it apart from conventional systems.

The solution is already in use at public hospitals in Lübeck and Bad Oeynhausen, as well as several private cardiology clinics.

📸 Photo from DGK Herztage in Hamburg, together with our German distribution partner .

31/08/2025

Norwegian research at a world-class level!

At ESC 2025, the world’s largest cardiology congress, Norwegian cardiologists presented findings from NORSCREEN – one of the world’s largest randomized, controlled interventional studies on atrial fibrillation (AF).
This fully digital study includes 50,549 participants from across Norway.
The goal: To prevent stroke by detecting AF early, using ECG247.

Led by Professor Sigrun Halvorsen (OUS/UiO), the study marks a major step forward for digital patient monitoring.

Cardiologists Miroslav Boskovic and Marius Blørstad Haraldsen presented two sub-studies that gained significant attention during the congress in Madrid.

A strong recognition of Norwegian clinical research — and a clear signal of how digital tools and ECG247 can contribute to the prevention and treatment of atrial fibrillation.

🔗 Read more: dagensmedisin.no

09/07/2025

Advancing Arrhythmia Diagnostics: Insights from the Medical University of Lodz. At the International Congress on Electrocardiology 2025 (ISHNE & ISE) in Thessaloniki, Greece, experiences with the use of ECG247 at the Medical University of Lodz, Poland, were presented by Professor Andrzej Bissinger MD PhD FESC. He concluded that ECG247 can contribute to improved and more efficient arrhythmia diagnostics in clinical practice.

19/05/2025

🌟 Are you interested in learning more about the NORSCREEN study, the world's largest screening study for atrial fibrillation? Join us at the Startup Zone at to discover more! We look forward to seeing you there! 🌟

14/05/2025

ECG247 is excited to announce our presence at the conference in Helsinki, Finland, this year! We will be showcasing our innovative heart sensor, , in the start-up zone alongside other promising start-ups. We invite you to visit our booth to learn more about ECG247 and discover how our technology can effectively screen for atrial fibrillation. We look forward to connecting with you!

30/03/2025

Due to growing demand for ECG247 from hospitals and clinics in Norway and internationally, we are expanding our team. Our advanced solution for long-term heart rhythm monitoring has undergone significant technological advancements, making it a robust, scalable, and highly attractive option in variou...

11/01/2025

ECG247 in the Tromsø Study!

The Tromsø Study, initiated in 1974 in response to the high cardiovascular disease mortality rates in Northern Norway, has since evolved into a series of seven studies conducted at 7-8 year intervals. The eighth Tromsø Study is scheduled for 2025-2026 and will involve 4,000 participants with elevated NT-proBNP levels. Participants will be randomized to atrial fibrillation screening using ECG247. Outcomes in the intervention group will be compared to those in the control group regarding stroke incidence and mortality over a six-year follow-up period.

For ECG247, it is a vote of confidence that another leading research community chooses to use Norwegian medical technology. ECG247 is also in use in the Norwegian national atrial fibrillation screening study NORSCREEN and in the Nord-Trøndelag Health Study (HUNT). The ECG247 is highly cost-effective and requires minimal personnel resources.

08/01/2025

New trial published: ECG247 is highly suitable for evaluating heart rhythm disorders in athletes

Researchers from Bærum Hospital and St. Olavs Hospital, in collaboration with colleagues from Belgium and Australia, conducted a comparative study between ECG247 and implantable loop recorders. The study concluded that ECG247 is highly suitable for evaluating heart rhythm disorders in athletes, successfully detecting all arrhythmias identified by the loop recorders in the study participants.

This study represents another important clinical validation of ECG247. As a more cost-effective and user-friendly alternative to implantable loop recorders, ECG247 has the potential to facilitate faster patient evaluations and help reduce hospital waiting lists.

Read the paper in BMJ Open: https://bmjopen.bmj.com/content/15/1/e093250

22/11/2024

In the fourth Trøndelag Health Study (HUNT4, 2017-2019), NTNU, Trondheim, over 2,400 participants were examined with cardiac ultrasound and a treadmill exercise test. In a new project, these participants will now be examined for heart rhythm disorders with ECG247. The goal of the project is, among ...

Adresse

Senterveien 30
Lillesand
4790

Telefon

+4791369657

Nettsted

http://ecg247.com/

Varslinger

Vær den første som vet og la oss sende deg en e-post når ECG247 Smart Heart Sensor legger inn nyheter og kampanjer. Din e-postadresse vil ikke bli brukt til noe annet formål, og du kan når som helst melde deg av.

Kontakt Bedriften

Send en melding til ECG247 Smart Heart Sensor:

Snarveier

Vil du plassere din bedrift på toppen av Helse- Og Skjønnhetsbedrifter-listen i Lillesand?

Del

Type

Helse og medisin